Sanders launches investigation into ‘unacceptable’ diabetes, weight loss drug prices
- The U.S. Senate is investigating Novo Nordisk's high prices for weight loss and diabetes drugs Ozempic and Wegovy.
- Novo Nordisk charges significantly less for the drugs in other countries than in the U.S., according to Sanders.
- Senator Sanders called for a reduction in the list and net prices of both Ozempic and Wegovy, questioning the pharmaceutical company's pricing strategies.
Insights by Ground AI
Does this summary seem wrong?
0 Articles
0 Articles
All
Left
Center
Right
Coverage Details
Total News Sources0
Leaning Left3Leaning Right1Center6Last Updated9 days agoBias Distribution60% Center